Symbiosis C.M.

Company Overview

Snapshot

Founded in February 2021 by Shira Burg, Symbiosis C.M. operates with 11–50 employees. The company has completed 5 funding rounds and holds 1 patent. In October 2024, Symbiosis C.M. won the Shark Tank innovation prize at TCT 2024.

Business overview

Symbiosis C.M. is a medical device company focused on addressing anatomical variability in valvular heart disease. The company develops solutions to improve the fit and performance of existing medical devices, as well as standalone products for anatomies with significant inter-patient variability. Its core product, ValSync, is designed as a minimally invasive personalized solution for valve replacement, serving the Health Tech & Life Sciences sector, specifically within medical devices and medical treatment & therapeutics.

Strategic signal

In October 2024, Symbiosis C.M. secured the Shark Tank innovation prize at TCT 2024, a significant validation of its personalized transcatheter heart valve replacement technology. This recognition highlights the company's potential to disrupt the medical device market by addressing critical challenges in valvular heart disease, signaling strong industry interest and a promising trajectory for its innovative solutions.

Company Intelligence Q&A

What is Symbiosis C.M.'s primary focus?

Symbiosis C.M. is an innovative medical device company dedicated to solving anatomical variability in valvular heart disease, aiming to improve the fit and performance of existing medical devices and develop standalone products.

What is ValSync?

ValSync is Symbiosis C.M.'s first product, designed as a minimally invasive personalized solution for valve replacement.

When was Symbiosis C.M. founded?

Symbiosis C.M. was founded in February 2021.

What significant recognition did Symbiosis C.M. receive in late 2024?

In October 2024, Symbiosis C.M. won the Shark Tank innovation prize at TCT 2024. In December 2024, the company also welcomed Prof. Marc Gillinov to its Advisory Board.

What was the focus of the article featuring ValSync development?

In November 2024, ValSync development was featured in JACC, highlighting the progress and significance of Symbiosis C.M.'s personalized heart valve solution.